Drug Profile
Pacmilimab - CytomX Therapeutics
Alternative Names: CX-072; PD-L1 probody therapeutic - CytomX TherapeuticsLatest Information Update: 21 Feb 2022
Price :
$50
*
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Solid tumours
- Phase I/II Lymphoma
Most Recent Events
- 06 Oct 2021 CytomX Therapeutics completed the phase I/II trial in Solid tumours and Lymphoma (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease, Recurrent, Unresectable/Inoperable, Second-line therapy or greater) in USA, Netherlands, Ukraine, United Kingdom, Poland, Hungary and Spain (NCT03013491) (EudraCT2016-002490-36)
- 04 Aug 2021 Pharmacodynamics and pharmacokinetics data from preclinical studies in solid tumours released by CytomX Therapeutics
- 04 Aug 2021 Updated efficacy and adverse events data from the phase I/IIa PROCLAIM-072 trial in Solid tumours released by CytomX Therapeutics